Pierre Fabre Laboratories has announced that the European Commission (EC) has approved Braftovi (encorafenib) in combination with Mektovi (binimetinib) for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with a BRAFV600E mutation.
The products have already won approvals in metastatic melanoma and colorectal cancer indications in the EC and multiple other geographies.
US pharma giant Pfizer (NYSE: PFE) has exclusive rights to commercialize Braftovi and Mektovi in the USA, Canada, and all countries in the Latin American, African, and Middle Eastern regions, while Japan’s Ono Pharmaceutical (TYO: 4528) has exclusive rights to commercialize both products in Japan and South Korea. Medison has exclusive rights in its home country of Israel. Pierre Fabre has exclusive rights in all other countries, including Europe and Asia-Pacific.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze